Rosacea News and Research

Latest Rosacea News and Research

Ipsen's Azzalure muscle relaxant receives Spanish AEMPS marketing approval

Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.

21 Sep 2009

Signum Biosciences awarded $1.6 million SBIR Phase II grant

Signum Biosciences, Inc has been awarded a $1.6 million Small Business Innovation Research (SBIR) Phase II grant by the National Institute of Allergy and Infection Diseases (NIAID) to continue the development of its topical STM (Signal Transduction Modulator) anti-inflammatory technology for the treatment of inflammatory skin disease.

11 Sep 2009

Results of Phase 2 rheumatoid arthritis clinical trial announced

Array BioPharma Inc. (Nasdaq: ARRY) announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients.

4 Sep 2009

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Asset Purchase Agreement Signed for Marketed Prescription Products Desonate(R) and NeoBenz(R) Micro

3 Sep 2009

Mylan confirms four first-to-file challenges

Mylan Inc. has announced that it and/or a subsidiary have been sued in connection with four separate "first-to-file" Abbreviated New Drug Applications (ANDA) filed with the U.S. Food and Drug Administration (FDA).

29 Mar 2009

Galderma to acquire CollaGenex Pharmaceuticals

Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, and CollaGenex Pharmaceuticals, Inc. has announced a definitive agreement pursuant to which Galderma's U.S. holding company, Galderma Laboratories, Inc., will acquire all of the outstanding shares of CollaGenex at a price of $16.60 per share in cash, representing approximately $420 million for the equity of CollaGenex.

27 Feb 2008

FDA warns Melanocorp for illegal sale of Melanotan II

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to Brian Manookian, owner of Melanocorp, Inc. in Hendersonville, Tenn. for the illegal sale and marketing of the product Melanotan II, which is not FDA-approved, on Melanocorp's Web site.

5 Sep 2007

What causes rosacea?

Doctors can describe the symptoms of rosacea, a common inflammatory skin disease that causes facial redness and affects nearly 14 million Americans.

6 Aug 2007

Rosacea the result of a trifecta of unfortunate factors

Rosacea is a common inflammatory skin disease that causes facial redness which affects as many as 14 million Americans.

6 Aug 2007

New oral acne medications work best

While laser and light-based therapies continue to make their mark on many dermatologic procedures, some dermatologists believe the tried-and-true oral medications for treating moderate to severe acne offer patients the best long-term treatment outcomes.

2 Aug 2007

New Rosacea treatment kit

Galderma Laboratories, L.P. has announced the availability of a new MetroGel 1% Kit for the topical treatment of the inflammatory lesions of rosacea.

14 Jan 2007

New skin care regimen proves effective for Rosacea

Rosacea is a disabling skin condition characterized by facial redness and has historically been challenging to treat.

30 May 2006

Individualized treatment options for rosacea

Many individuals who are struggling with redness, pimples and visible blood vessels on their face may incorrectly diagnose their condition as acne, sunburn or sensitive skin.

6 Mar 2006

Innovative laser and light treatments to tackle acne, rosacea, sun damage and signs of aging

Millions of Americans suffer from skin conditions that affect their appearance and can cause emotional and social distress. Thanks to technological advances, many of these conditions are treatable with laser and light therapies which offer a faster way to improve appearance with less recovery time and a higher degree of safety.

21 Jul 2005

New treatment for rosacea

Galderma Laboratories has announced FDA approval of a new product for the topical treatment of the inflammatory lesions of rosacea. MetroGel (metronidazole) Topical Gel, 1% will be available by prescription July 29, 2005. The new medication incorporates a higher concentration of metronidazole in a new, technologically advanced vehicle.

6 Jul 2005

Common clinical problem, Rosacea

A number of clinical symptoms and signs are included under the broad group Rosacea. Facial flushing, the appearance of broken blood vessels and persistent redness of the face, eruption of inflamed spots & pimples, on the face and thickening of the sebaceous glands of the nose, with swelling & congestion in that area.

24 Feb 2005